(SGRY) Surgery Partners - Overview

Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NASDAQ (USA) | Market Cap: 1.675m USD | Total Return: -38.6% in 12m

Surgical Centers, Hospitals, Physician Practices, Urgent Care, Anesthesia
Total Rating 31
Safety 62
Buy Signal -0.42
Medical Care Facilities
Industry Rotation: -7.7
Market Cap: 1.67B
Avg Turnover: 11.9M USD
ATR: 4.07%
Peers RS (IBD): 2.6
Risk 5d forecast
Volatility47.8%
Rel. Tail Risk-13.0%
Reward TTM
Sharpe Ratio-0.85
Alpha-63.10
Character TTM
Beta0.729
Beta Downside1.301
Drawdowns 3y
Max DD74.52%
CAGR/Max DD-0.40
EPS (Earnings per Share) EPS (Earnings per Share) of SGRY over the last years for every Quarter: "2021-03": -0.3, "2021-06": -0.0016, "2021-09": -0.05, "2021-12": 0.23, "2022-03": -0.09, "2022-06": -0.03, "2022-09": -0.02, "2022-12": 0.27, "2023-03": 0.08, "2023-06": 0.28, "2023-09": 0.19, "2023-12": 0.44, "2024-03": 0.1, "2024-06": 0.21, "2024-09": -0.2512, "2024-12": 0.44, "2025-03": 0.04, "2025-06": -0.02, "2025-09": 0.13, "2025-12": 0.12,
EPS CAGR: 23.53%
EPS Trend: 10.4%
Last SUE: -0.97
Qual. Beats: 0
Revenue Revenue of SGRY over the last years for every Quarter: 2021-03: 512.4, 2021-06: 543.3, 2021-09: 559.2, 2021-12: 610.2, 2022-03: 596.2, 2022-06: 615.4, 2022-09: 620.6, 2022-12: 707.1, 2023-03: 666.2, 2023-06: 667.6, 2023-09: 674.1, 2023-12: 735.4, 2024-03: 717.4, 2024-06: 762.1, 2024-09: 770.4, 2024-12: 864.4, 2025-03: 776, 2025-06: 826.2, 2025-09: 821.5, 2025-12: 885,
Rev. CAGR: 11.11%
Rev. Trend: 94.9%
Last SUE: 1.22
Qual. Beats: 1

Warnings

Altman Z'' 0.56 < 1.0 - financial distress zone

Choppy

Tailwinds

No distinct edge detected

Description: SGRY Surgery Partners

Surgery Partners, Inc. (SGRY) operates a national network of ambulatory surgery centers (ASCs) and surgical hospitals across the United States. The company focuses on high-growth, non-emergency specialties including orthopedics, ophthalmology, and gastroenterology, while providing supporting services such as anesthesia and urgent care.

The business model relies on the ongoing shift of surgical procedures from high-cost inpatient hospital settings to lower-cost outpatient facilities. In the Health Care Facilities sector, ASCs typically benefit from higher specialized physician engagement and improved operational efficiency compared to traditional general hospitals.

Investors can further evaluate the companys financial health and valuation metrics on ValueRay. Founded in 2004 and based in Brentwood, Tennessee, the firm manages a diverse portfolio of both single- and multi-specialty surgical sites.

Headlines to Watch Out For
  • Ambulatory surgery volume growth boosts revenue
  • Physician recruitment and retention impacts service capacity
  • Reimbursement rates from insurers dictate profitability
  • Healthcare regulatory changes pose operational risks
Piotroski VR‑10 (Strict) 3.5
Net Income: -77.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.28 > 1.0
NWC/Revenue: 16.18% < 20% (prev 15.89%; Δ 0.28% < -1%)
CFO/TA 0.03 > 3% & CFO 274.3m > Net Income -77.9m
Net Debt (3.78b) to EBITDA (950.7m): 3.98 < 3
Current Ratio: 1.87 > 1.5 & < 3
Outstanding Shares: last quarter (127.2m) vs 12m ago 0.79% < -2%
Gross Margin: 23.12% > 18% (prev 0.24%; Δ 2.29k% > 0.5%)
Asset Turnover: 41.02% > 50% (prev 39.47%; Δ 1.55% > 0%)
Interest Coverage Ratio: 1.18 > 6 (EBITDA TTM 950.7m / Interest Expense TTM 657.8m)
Altman Z'' 0.56
A: 0.06 (Total Current Assets 1.15b - Total Current Liabilities 615.5m) / Total Assets 8.24b
B: -0.10 (Retained Earnings -815.2m / Total Assets 8.24b)
C: 0.10 (EBIT TTM 774.7m / Avg Total Assets 8.07b)
D: -0.18 (Book Value of Equity -827.7m / Total Liabilities 4.72b)
Altman-Z'' Score: 0.56 = B
Beneish M -3.01
DSRI: 0.98 (Receivables 602.2m/579.1m, Revenue 3.31b/3.11b)
GMI: 1.04 (GM 23.12% / 23.94%)
AQI: 1.00 (AQ_t 0.69 / AQ_t-1 0.68)
SGI: 1.06 (Revenue 3.31b / 3.11b)
TATA: -0.04 (NI -77.9m - CFO 274.3m) / TA 8.24b)
Beneish M-Score: -3.01 (Cap -4..+1) = AA
What is the price of SGRY shares? As of April 16, 2026, the stock is trading at USD 13.10 with a total of 715,372 shares traded.
Over the past week, the price has changed by +3.64%, over one month by +5.73%, over three months by -14.99% and over the past year by -38.56%.
Is SGRY a buy, sell or hold? Surgery Partners has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy SGRY.
  • StrongBuy: 8
  • Buy: 1
  • Hold: 3
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the SGRY price?
Analysts Target Price 18.8 43.5%
Surgery Partners (SGRY) - Fundamental Data Overview as of 11 April 2026
P/E Forward = 35.8423
P/S = 0.5061
P/B = 0.9203
P/EG = 1.66
Revenue TTM = 3.31b USD
EBIT TTM = 774.7m USD
EBITDA TTM = 950.7m USD
Long Term Debt = 3.60b USD (from longTermDebt, last quarter)
Short Term Debt = 142.0m USD (from shortTermDebt, last quarter)
Debt = 4.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.78b USD (from netDebt column, last quarter)
Enterprise Value = 5.46b USD (1.67b + Debt 4.02b - CCE 239.9m)
Interest Coverage Ratio = 1.18 (Ebit TTM 774.7m / Interest Expense TTM 657.8m)
EV/FCF = 27.91x (Enterprise Value 5.46b / FCF TTM 195.6m)
FCF Yield = 3.58% (FCF TTM 195.6m / Enterprise Value 5.46b)
FCF Margin = 5.91% (FCF TTM 195.6m / Revenue TTM 3.31b)
Net Margin = -2.35% (Net Income TTM -77.9m / Revenue TTM 3.31b)
Gross Margin = 23.12% ((Revenue TTM 3.31b - Cost of Revenue TTM 2.54b) / Revenue TTM)
Gross Margin QoQ = 23.98% (prev 23.77%)
Tobins Q-Ratio = 0.66 (Enterprise Value 5.46b / Total Assets 8.24b)
Interest Expense / Debt = 4.79% (Interest Expense 192.6m / Debt 4.02b)
Taxrate = 31.92% (13.6m / 42.6m)
NOPAT = 527.4m (EBIT 774.7m * (1 - 31.92%))
Current Ratio = 1.87 (Total Current Assets 1.15b / Total Current Liabilities 615.5m)
Debt / Equity = 2.35 (Debt 4.02b / totalStockholderEquity, last quarter 1.71b)
Debt / EBITDA = 3.98 (Net Debt 3.78b / EBITDA 950.7m)
Debt / FCF = 19.35 (Net Debt 3.78b / FCF TTM 195.6m)
Total Stockholder Equity = 1.73b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.97% (Net Income -77.9m / Total Assets 8.24b)
RoE = -4.50% (Net Income TTM -77.9m / Total Stockholder Equity 1.73b)
RoCE = 14.52% (EBIT 774.7m / Capital Employed (Equity 1.73b + L.T.Debt 3.60b))
RoIC = 9.89% (NOPAT 527.4m / Invested Capital 5.33b)
WACC = 4.81% (E(1.67b)/V(5.70b) * Re(8.55%) + D(4.02b)/V(5.70b) * Rd(4.79%) * (1-Tc(0.32)))
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.57%
[DCF] Terminal Value 87.47% ; FCFF base≈201.2m ; Y1≈227.4m ; Y5≈307.9m
[DCF] Fair Price = 40.53 (EV 9.03b - Net Debt 3.78b = Equity 5.25b / Shares 129.4m; r=6.0% [WACC]; 5y FCF grow 15.09% → 3.0% )
EPS Correlation: 10.44 | EPS CAGR: 23.53% | SUE: -0.97 | # QB: 0
Revenue Correlation: 94.91 | Revenue CAGR: 11.11% | SUE: 1.22 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.03 | Chg7d=-0.004 | Chg30d=-0.112 | Revisions Net=-3 | Analysts=10
EPS current Year (2026-12-31): EPS=0.20 | Chg7d=-0.034 | Chg30d=-0.486 | Revisions Net=-7 | Growth EPS=-57.0% | Growth Revenue=+3.0%
EPS next Year (2027-12-31): EPS=0.40 | Chg7d=-0.040 | Chg30d=-0.450 | Revisions Net=-5 | Growth EPS=+98.4% | Growth Revenue=+5.5%
[Analyst] Revisions Ratio: -0.60 (1 Up / 4 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle